New research offers hope for early intervention

Berlin: Researchers in Michael Sigal's lab at the Max Delbruck Center and Charite - Universitatsmedizin Berlin have discovered the significance of the p53

Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder characterized by the misfolding and accumulation of the mutant variant of alpha-1 antitrypsin (AAT) within hepatocytes, which limits its access to the circulation and exposes the lungs to protease-mediated tissue damage.

The effect of tenofovir amibufenamide (TMF) on blood lipid profiles in patients with chronic hepatitis B (CHB) remains unclear. This study aimed to explore whether TMF affects blood lipids during 48 weeks in patients with CHB.

Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 diabetes and congestive heart failure. Reports of GLP-1RA–associated acute kidney injury (AKI) have emerged, but the risk of GLP-1RA–associated AKI among patients on anti-cancer drugs is unclear.

The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) recently awarded a $3.7 million grant to support a project led by Principal Investigator, Chase Kessinger, Ph.D., assistant professor of biomedical research and translational medicine at Masonic Medical Research Institute (MMRI) to research the third most common cause of cardiovascular death, pulmonary embolism (PE).

The diabetes drug semaglutide, also known as Ozempic, has a positive effect for patients with chronic kidney damage and obesity. They

Researchers in the lab of Michael Sigal at the Max Delbrück Center and Charité – Universitätsmedizin Berlin have elucidated the role of the p53 gene in ulcerative colitis.

Data regarding risk factors and long-term outcomes of U.S. patients with biopsy-proven metabolic dysfunction-associated steatotic liver disease (MASLD) are limited.

Despite significant advancements in cancer treatment, drug resistance remains a persistent challenge. Cancer cells can often develop resistance to treatments such as chemotherapy, radiotherapy, and immunotherapy, leading to reduced treatment efficacy.

Investigators recently uncovered key insights into newly defined rejection entities in kidney transplantation that may offer improved patient risk categorization post-transplant. The research will be presented at ASN Kidney Week 2024 October 23– 27.

Researchers use real-world data in the United States to evaluate the protective role of semaglutide against Alzherimer’s disease.

Researchers from Mass General Brigham and collaborators found that use of GLP-1 drugs to treat obesity more than doubled from 2022 to 2023 while rates of surgery dropped by one quarter.